There are two companies Arsanis and Adimab which focus on developing monoclonal antibodies, and their most recent target has been RSV. They have just gained a worldwide license to antibodies targeting RSV which were discovered at Adimab. They discovered the antibodies using optimized yeats-based platforms. In the current plan Adimab’s panel of antibodies will be released to Arsanis which will evaluate them and select the best therapeutic. This is an important step as currently there are no therapeutics for RSV which is a very common virus in fection and is highly contagious. It is particularly dangerous to elderly and immunocompromised people. This is not the only company that has its eyes set on RSV. NovaVax has a RSV vaccine candidate in phase 3 trials and Ablynx is in phase 2a trials of a RSV inhalable nanobody for infants. We shall see which treatment method becomes standard practice in the near future.